Incyte and Novartis settle Jakafi royalty dispute with a $280M payment and future royalty rate cuts. Read more here.

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

Incyte Corporation INCY is expected to beat estimates when it reports first-quarter 2025 earnings results on April 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported ...

Incyte also earns product royalty revenues from Novartis NVS for the commercialization of Jakafi in ex-U.S. markets. While Incyte markets Jakafi in the United States, Novartis markets the same ...

The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis ...

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

1 Novartis’ rights to ruxolitinib outside of ... Other - key highlights In February 2025, Incyte and Genesis Therapeutics, Inc. (Genesis) entered into a strategic collaboration focused on ...

Patients with advanced solid tumors experienced significantly improved survival outcomes with tailored treatment guided by tissue plus liquid biopsies vs. individually, according to results presented ...